Julie R. Brahmer, MD
Advertisement

Julie Brahmer, MD, MSc, is the co-director of the Upper Aerodigestive Department at the Bloomberg-Kimmel Institute for Cancer Immunotherapy, the co-director of the Cancer Immunotherapy Program, the director of Thoracic Oncology, and the Marilyn Meyerhoff Professor in Thoracic Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Articles by Julie R. Brahmer, MD
Advertisement
Latest Updated Articles
Is There a Role for Immunotherapy in Patients with KRAS G12C-Mutant NSCLC and STK11 or KEAP1 Co-Mutations?Published: September 19th 2023 | Updated:
Dr. Brahmer on the Examination of Nemvaleukin Alfa in Solid TumorsPublished: July 16th 2022 | Updated:
Emerging Treatment Options for Patients with NSCLC with ALK RearrangementsPublished: September 19th 2023 | Updated:
Adagrasib for Patients with KRAS G12C–Mutant NSCLCPublished: September 12th 2023 | Updated:
Dr. Brahmer on Emerging Targeted Therapies in EGFR Exon 20–Mutated Lung CancerPublished: February 10th 2021 | Updated:
Dr. Brahmer on Treatment Following Progression on First-line Immunotherapy in NSCLCPublished: March 8th 2023 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
5

